Inflammation-Triggered Cancer Immunotherapy by Programmed Delivery of CpG and Anti-PD1 Antibody

Inflammation-Triggered Cancer Immunotherapy by Programmed Delivery of CpG and Anti-PD1 Antibody

Inflammation‐triggered combination delivery of anti‐PD‐1 antibody and CpG oligodeoxynucleotides (CpG ODNs) has been demonstrated to prevent cancer relapse utilizing postsurgical inflammatory response. The controlled release of anti‐PD1 and CpG ODN by CpG DNA‐based "nano‐cocoons" can induce...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Advanced materials (Weinheim) 2016-10, Vol.28 (40), p.8912-8920
Hauptverfasser: Wang, Chao, Sun, Wujin, Wright, Grace, Wang, Andrew Z., Gu, Zhen
Format: Artikel
Sprache:eng
Schlagworte:
Adjuvants, Immunologic
Animals
anti-PD1
Antibodies
Cancer
cancer immunotherapy
Controlled release
CpG
CpG Islands
drug delivery
Immune systems
Immunotherapy
Inflammation
Inflammatory response
Mice
nanobiotechnology
Nanostructure
Neoplasms - therapy
Programmed Cell Death 1 Receptor - immunology
Survival
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Inflammation‐triggered combination delivery of anti‐PD‐1 antibody and CpG oligodeoxynucleotides (CpG ODNs) has been demonstrated to prevent cancer relapse utilizing postsurgical inflammatory response. The controlled release of anti‐PD1 and CpG ODN by CpG DNA‐based "nano‐cocoons" can induce considerable immune response, which in turn significantly prolongs the survival time of mice.
ISSN:0935-9648
1521-4095
DOI:10.1002/adma.201506312